Clinical Trial Detail

NCT ID NCT02538627
Title Phase 1 Combination Study of MM-151 and MM-121
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Merrimack Pharmaceuticals
Indications

head and neck cancer

colorectal cancer

lung cancer

Therapies

Seribantumab

MM-151

Age Groups: adult

Additional content available in CKB BOOST